ReviewJournal of advanced research2015
A mini review on cancer of unknown primary site: A clinical puzzle for the oncologists.
Review in Journal of advanced research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Risk factors for cancer of unknown primary: a literature review.BMC cancer · 2023Pooled it
- The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review.Frontiers in oncology · 2020Pooled it
- Cancer of unknown primary: the evolution of tissue of origin identification in the artificial intelligence era.Biomarker research · 2026Review
- Integrative cfDNA profiling from low-pass whole-genome sequencing enables tissue-of-origin prediction in cancer.Molecular biomedicine · 2026Article
- Article
- Learning Patient Similarity from Genomics for Precision Oncology.medRxiv : the preprint server for health sciences · 2025Article
- Clinical outcome and genomic biomarkers of immune checkpoint inhibitor-based therapies for cancer of unknown primary: a multicenter, real-world study.Journal of cancer research and clinical oncology · 2025Article
- Exploration of genes related to the development of cancer of unknown primary.Oncology reports · 2025Article
- Impact of whole genome sequencing on the care pathway for patients with cancer of unknown primary.ESMO open · 2025Article
- Article
- A machine learning-based method for feature reduction of methylation data for the classification of cancer tissue origin.International journal of clinical oncology · 2024Article
- PathMethy: an interpretable AI framework for cancer origin tracing based on DNA methylation.Briefings in bioinformatics · 2024Article
- Tracing unknown tumor origins with a biological-pathway-based transformer model.Cell reports methods · 2024Article
- Unveiling the best predictive models for early‑onset metastatic cancer: Insights and innovations (Review).Oncology reports · 2024Review
- Review
- Advances in Cancer Research: Current and Future Diagnostic and Therapeutic Strategies.Biosensors · 2024Review
- Cancer of unknown primary histologically, genetically and spatially diagnosed as left ovary‑derived cancer: A case report.Oncology letters · 2023Article
- Carcinoma of unknown primary (CUP): an update for histopathologists.Cancer metastasis reviews · 2023Review
- Local Treatment Efficacy for Single-Area Squamous Cell Carcinoma of the Unknown Primary Site.Current oncology (Toronto, Ont.) · 2023Article
- Survival Outcome in True Carcinoma of Unknown Primary (tCUP) with p16 + Cervical Metastasis.International archives of otorhinolaryngology · 2023Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer of unknown primary (CUP) is a well recognized clinical syndrome, accounting for 3-5% of all malignancies. It is characterized as a disease with an early dissemination of metastases without a primary detected site after extensive laboratory and clinical investigations. CUP is divided into the favorable and unfavorable groups based on histopathological and clinical manifestations. Adenocarcinoma of various differentiations is the commonest histopathological subtype. Favorable groups are treated with local or systemic treatment and some of them are enjoying long-term survival. On the contrary, unfavorable groups are treated with empirical chemotherapy having usually a dismal prognosis. Gene-profiling microarray diagnosis has a high diagnostic sensitivity, but its predictive or prognostic value remains uncertain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.